Home Intravenous Antibiotic Therapy

  • Richard B. Brown


The delivery of home therapy has become one of the most rapidly growing sectors of the health care industry.1 Since 1971 Medicare expenditures for home health care have grown by 20% annually, while Medicaid costs in this area have risen from approximately $15 million to over $400 million.2 Overall vists to patients at home have tripled.2 Intravenous therapy constitutes the largest single portion of this market and consists of the delivery of home intravenous antibiotics, parenteral nutrition, cancer chemotherapy, and pain management.1 This entire market is expected to experience a 34% rate of growth through at least 1990, and it is anticipated that the market will have a rise in revenues from $850 million in 1986 to at least $2.8 billion by 1990.3 Of these, the delivery of intravenous antibiotics is expected to experience the most rapid growth over the next several years. This sector is anticipated to grow about tenfold from approximately $122 million in 1986 to over $1.3 billion in 1990 and by that time may account for 50% of the total home infusion market.3


Infective Endocarditis Septic Arthritis Home Health Care Intravenous Antibiotic Therapy Home Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rucker BB, Holmstedt KA: Home Infusion Therapy Industry. San Francisco, Hambrecht and Quist, 1984.Google Scholar
  2. 2.
    Koren MJ: Home care-Who cares? N Engl J Med 1986; 314: 917–920.PubMedCrossRefGoogle Scholar
  3. 3.
    Hambrecht and Quist 1987 Report: Home infusion therapy industry to maintain 34% growth while small companies reshape market, stimulate demand. Home Health Line, 9 Feb 1987.Google Scholar
  4. 4.
    Nelson JD: A critical review of the role of oral antibiotics in the management of hematogenous osteomyelitis. In: Remington JS, Swartz MN, eds. Current Clinical Topics in Infectious Disease, vol 4. New York, McGraw-Hill, 1983: 64–74.Google Scholar
  5. 5.
    Siegel D: Management of community-acquired pneumonia in outpatients. West J Med 1985; 142: 45–48.PubMedGoogle Scholar
  6. 6.
    Scheid WM, Sande MA: Endocarditis and intravascular infections. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Disease, ed 2. New York, John Wiley & Sons, 1985: 504–530.Google Scholar
  7. 7.
    Norden CW: Osteomyelitis. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Disease, ed 2. New York, John Wiley & Sons, 1985: 704–711.Google Scholar
  8. 8.
    Levison ME, Pontzer RE: Peritonitis and other intra-abdominal infections. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Disease, ed 2. New York, John Wiley & Sons, 1985: 476–503.Google Scholar
  9. 9.
    Rucker RW, Harrison GM: Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 1974; 54: 358–360.PubMedGoogle Scholar
  10. 10.
    Antonisdis A, Anderson BC, van Volkinburg EJ, et al: Feasibility of outpatient self-administration of parenteral antibiotics. West J Med 1978; 128: 203–206.Google Scholar
  11. 11.
    Stiver HG, Telford GO, Mossey JM, et al: Intravenous antibiotic therapy at home. Ann Intern Med 1978; 89: 690–693.PubMedCrossRefGoogle Scholar
  12. 12.
    Stiver HG, Trosky SK, Cote DD, et al: Self-administration of intravenous antibiotics: An efficient, cost effective home care program. Can Med Assoc J 1982; 127: 207–211.PubMedGoogle Scholar
  13. 13.
    Poretz DM, Eron LJ, Goldenberg RI, et al: Intravenous antibiotic therapy in an outpatient setting. JAMA 1982; 248: 336–339.Google Scholar
  14. 14.
    Kind AC, Williams DN, Persons G, et al: Intravenous antibiotic therapy at home. Arch Intern Med 1979; 139: 412–415.CrossRefGoogle Scholar
  15. 15.
    Eisenberg JM, Kitz DS: Savings from outpatient antibiotic therapy for osteomyelitis. JAMA 1986; 255: 1584–1588.Google Scholar
  16. 16.
    Poretz DM, Woolard D, Eron LJ, et al: Outpatient use of ceftriaxone: A cost-benefit analysis. Am J Med 1984; 77 (suppl 4C): 77–84.PubMedGoogle Scholar
  17. 17.
    Kamen BA, Gunther N: Administering a 24-hour supply of antibiotics with a programmable, automated syringe pump. Am J Hosp Pharm 1985; 42: 2715–2716.PubMedGoogle Scholar
  18. 18.
    Goldenberg R, Poretz DM, Eron LJ, et al: Intravenous antibiotic therapy in ambulatory pediatric patients. Pediatr Infect Dis 1984; 3: 514–517.PubMedCrossRefGoogle Scholar
  19. 19.
    Smego RA: Home intravenous antibiotic therapy. Arch Intern Med 1985; 145: 1001–1002.PubMedCrossRefGoogle Scholar
  20. 20.
    Rehm SJ, Weinstein AJ: Home intravenous antibiotic therapy: A team approach. Ann Intern Med 1983; 99: 388–392.PubMedCrossRefGoogle Scholar
  21. 21.
    Schuman ES: Outpatient management of Hickman catheter sepsis. Infect Surg 1987; 6: 103–106.Google Scholar
  22. 22.
    Health and Public Policy Committee, American College of Physicians: Home health care. Ann Intern Med 1986; 105: 454–460.CrossRefGoogle Scholar
  23. 23.
    Rehm SJ: Home intravenous antibiotic therapy. Cleve Clin Q 1985; 52: 333–338.PubMedGoogle Scholar
  24. 24.
    Sorbello AF, Echols RM, Condoluci DV: Clinical efficacy of once-daily ceftriaxone therapy. Infect Med 1987; 4: 69–78.Google Scholar
  25. 25.
    Jauregui LE, Bischoff MC, Hageage GJ: Combined inpatient-outpatient therapy of serious infections with a single daily dose of ceftriaxone. In: Progress in Therapy of Bacterial Infection-A New Cephalosporin: Ceftriaxone. Amsterdam, Excerpta Medica, 1983: 104–122.Google Scholar
  26. 26.
    Patel IH, Kaplan SA: Pharmacokinetic profile of ceftriaxone in man. Am J Med 1984; 77 (suppl 4C): 17–25.PubMedGoogle Scholar
  27. 27.
    Cleeland R, Squires E: Antimicrobial spectrum of ceftriaxone: A review. Am J Med 1984; 77 (suppl 4C): 3–11.PubMedGoogle Scholar
  28. 28.
    Geraci JE: Vancomycin. Mayo Clin Proc 1977; 52: 631–634.PubMedGoogle Scholar
  29. 29.
    Woodley DW, Hall WH: The treatment of severe staphylococcal infections with vancomycin. Ann Intern Med 1961; 55: 235–249.PubMedCrossRefGoogle Scholar
  30. 30.
    Geraci JE, Hermans PE: Vancomycin. Mayo Clin Proc 1983; 58: 88–91.PubMedGoogle Scholar
  31. 31.
    Norris SM, Limon L: Vancomycin-new uses for an old drug. Infect Control 1984; 5: 302–404.Google Scholar
  32. 32.
    Weinstein Ai: The cephalosporins. Infect Dis Pract 1983; 6: 1–7.Google Scholar
  33. 33.
    The Medical Letter: Choice of cephalosporins. Med Lett 1983; 25:57–60.Google Scholar
  34. 34.
    Barza M, Miao PVW: Antimicrobial spectrum, pharmacology, and therapeutic use of antibiotics. Part 3: Cephalosporins. Am J Hosp Pharm 1977; 34: 621–629.PubMedGoogle Scholar
  35. 35.
    Carone SM, Bornstein M, Coleman DL, et al: Stability of frozen solutions of cefazolin sodium. Am J Hosp Pharm 1976; 33: 639–641.PubMedGoogle Scholar
  36. 36.
    Smego RA, Gainer RB: Home intravenous antimicrobial therapy provided by a community hospital and a university hospital. Am J Hosp Pharm 1985; 42: 2185–2189.PubMedGoogle Scholar
  37. 37.
    Harris LF, Buckle TF, Coffey FL Jr: Intravenous antibiotics at home. South Med J 1986; 79: 193–196.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Richard B. Brown

There are no affiliations available

Personalised recommendations